Scorpius Holdings Reports Officer and Director Changes
Ticker: SCPX · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1476963
| Field | Detail |
|---|---|
| Company | Scorpius Holdings, Inc. (SCPX) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance
Related Tickers: SCPX
TL;DR
Scorpius Holdings (SCPX) filing shows leadership changes effective Sept 22.
AI Summary
Scorpius Holdings, Inc. filed an 8-K on October 1, 2025, reporting changes effective September 22, 2025. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. The company was formerly known as NightHawk Biosciences, Inc. and HEAT BIOLOGICS, INC.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in key personnel and officer appointments can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Scorpius Holdings, Inc. (company) — Registrant
- NightHawk Biosciences, Inc. (company) — Former Company Name
- HEAT BIOLOGICS, INC. (company) — Former Company Name
- September 22, 2025 (date) — Effective Date of Changes
- October 1, 2025 (date) — Filing Date
FAQ
What specific officer positions have seen changes?
The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', but does not specify the exact positions in the provided text.
Who are the new directors or officers appointed?
The provided text does not name the specific individuals appointed as new directors or officers.
What are the reasons for the departure of any officers or directors?
The filing mentions the 'Departure of Directors or Certain Officers' but does not detail the reasons for these departures in the provided excerpt.
What is the nature of the compensatory arrangements for the officers?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specifics of these arrangements are not detailed in the provided text.
When did Scorpius Holdings, Inc. change its name from NightHawk Biosciences, Inc.?
The date of the name change from NightHawk Biosciences, Inc. to Scorpius Holdings, Inc. was May 2, 2022.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-10-01 16:15:37
Filing Documents
- scpx_8k.htm (8-K) — 23KB
- 0001079973-25-001531.txt ( ) — 179KB
- scpx-20250922.xsd (EX-101.SCH) — 3KB
- scpx-20250922_lab.xml (EX-101.LAB) — 33KB
- scpx-20250922_pre.xml (EX-101.PRE) — 22KB
- scpx_8k_htm.xml (XML) — 3KB
02. Departure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2025, the Board of Directors (the "Board") of Scorpius Holdings, Inc., a Delaware corporation (the "Company"), appointed Kit Foo Chye to serve as a director of the Company. Mr. Chye was not appointed to serve as a member of any committees of the Board. Mr. Chye, age 57, is currently, and has served since January 2018, as the Head of Corporate Finance at JS Group, an investment banking firm. From March 2012 to January 2018, Mr. Chye served as the Head of Corporate Finance of Sanston Securities Australia. Mr. Chye served as a director of Rocklands Richfield Limited from January 2005 to January 2012, Mr. Chye was a director of Hudson Resources Ltd., Allmine Group Limited, Sheng He Global Capital Ltd. and Synergy Metals Ltd. Mr. Chye holds a Bachelor of Commerce from Deakin University Australia. Mr. Chye will receive the standard compensation available to the Company's current non-employee directors. There are no family relationships between Mr. Chye and any of the Company's directors or executive officers, nor does he have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Other than as described above, there were no arrangements or understandings by which Mr. Chye was appointed as a member of the Board.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 1, 2025 SCORPIUS HOLDINGS, INC. By: /s/ Jeffrey Wolf Name: Jeffrey Wolf Title: Chairman, President and Chief Executive Officer